Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Sleepman who wrote (14646)	2/11/1998 7:18:00 PM
From: Andrew H	Respond to of 32384

Mr Tucker? Absolutely worthless. They will start the trials with a P2 whenever they choose to. It is exciting news, not only for LGND but especially for the multitudes of women who are devastated by this disease!! Just as there was no P1 for diabetes, there will be none here. If I remember, Targretin showed very promising preclinicals for emphysema as well. You are right about off label usage.

To: Sleepman who wrote (14646)	2/11/1998 7:20:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Dan, you are correct about the Phases. If it's monotherapy, Targretin will definitely begin as Phase II for breast cancer, just as it did for the other cancers (it's already been shown to be safe in cancer patients). As far a approvals are concerned, oral Targretin is in three Phase II/III studies (early CTCL, advanced CTCL, and advanced lung cancer) and LGND (and analysts) expect an NDA filing THIS YEAR. Approval for CTCL will almost certainly lead to off-label use (which Robinson has said will be "significant") as long as there is any positive clinical data. A combination trial with Tamoxifen and Targretin would probably be Phase I. However, two Phase I combination trials for Panretin and Tamoxifen for treating advanced breast cancer began in the middle of last year and should be ready to move into Phase II, if response is positive.